Effect of Pirfenidone on Treatment-emergent (TE) All-cause Mortality (ACM) in Patients with Idiopathic Pulmonary Fibrosis (IPF): Pooled Data Analysis from ASCEND and CAPACITY
U Costabel, SD Nathan, C Albera, WZ Bradford, EA Fagan, I Glaspole, MK Glassberg, D Kardatzke, TE King, KU Kirchgaessler, L Lancaster, DJ Lederer, CA Pereira, JJ Swigris, D Valeyre, PW Noble · Pneumologie · 2016 · Heft 02
Bibliografische Angaben
Zusammenfassung
Background: Pooled analysis of the ASCEND and CAPACITY studies showed a significant reduction in the risk of ACM over 52 weeks in patients with IPF treated with pirfenidone compared with placebo, and a nonsignificant trend favoring pirfenidone over the entire study period (up to week 120). Objective: To evaluate TE ACM over the full duration of observation in the pooled population from ASCEND and CAPACITY. Methods: TE ACM at last vital status assessment was evaluated in 1247 patients. TE deaths occurred after the first pirfenidone dose and within 28 days of the last dose. KaplanMeier estimates were used to summa…
